EE324 Cost-Effectiveness analysis of Atezolizumab as Adjuvant Treatment of Patients With Stage II-IIIA Non-Small Cell Lung Cancer, With Pd-L1≥50% of Tumor Cells, in France

I Plessala,C Chouaid,Pj Souquet,H Cawston,J Cortes,K Le Lay,A Roula

doi:10.1016/j.jval.2022.09.570

EE324 Cost-Effectiveness analysis of Atezolizumab as Adjuvant Treatment of Patients With Stage II-IIIA Non-Small Cell Lung Cancer, With Pd-L1≥50% of Tumor Cells, in France

I Plessala, C Chouaid + Show 5 more

Open Access

https://doi.org/10.1016/j.jval.2022.09.570

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Dec 1, 2022
Citations: 1	License type: publisher-specific-oa

Affiliation: Hospices Civils de Lyon, Hôpital Lyon Sud, Laboratoire Vision Action Cognition

#Stage II-IIIA Non-small Cell Lung #II-IIIA Non-small Cell Lung Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The study aimed to assess the cost-effectiveness in France of atezolizumab monotherapy as adjuvant treatment following resection and platinum-based chemotherapy for patients with stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1≥50% of tumour cells vs best supportive care (BSC), excluding EGFR and ALK+.

Full Text